Buy the Post-Earnings Surge in Intuitive Surgical (ISRG) Stock?

Intuitive Surgical (ISRG) significantly exceeded Q3 expectations, reporting $2.5 billion in sales and $2.40 EPS, driven by a 22% increase in instrument and accessory revenue and a 20% rise in global da Vinci system procedures. The company raised its full-year da Vinci procedure growth forecast to 17%-17.5% and pro forma gross margin to 67%-67.5%, projecting strong sales and earnings growth for FY25 and FY26. This robust performance and positive outlook led to a more than 15% surge in ISRG stock post-earnings, reflecting strong demand for robotic-assisted surgical systems and expanding recurring revenue from its growing installed base of over 10,000 systems.

Analysis

Intuitive Surgical (ISRG) significantly surpassed Q3 expectations, reporting sales of $2.5 billion and an EPS of $2.40, beating estimates by 20%. This strong performance was driven by a 22% increase in instruments and accessories revenue, reflecting higher procedure volumes and utilization. Global da Vinci system surgeries also rose 20%, underscoring robust demand.

Strategic execution is evident in 427 da Vinci system placements in Q3, up from 379 prior year, and FDA-cleared software upgrades. Intuitive Surgical subsequently raised full-year da Vinci procedure growth expectations to 17%-17.5% and gross margin to 67%-67.5%. Zacks estimates project robust FY25 and FY26 sales growth of 18% and 12% respectively, alongside EPS increases of 11% and 12%.

ISRG stock surged over 15% post-earnings, reflecting highly positive investor sentiment and moving into positive territory for the year. While trading at a 64X forward earnings premium, the expanding installed base of over 10,000 systems is expected to boost recurring revenue. This recurring revenue potential, coupled with likely upward EPS revisions, could help normalize the valuation.

Key Decisions for Investors

• Investors should monitor the sustainability of procedure volume growth and system placements, as these are key drivers for recurring revenue from instruments and accessories.
• Evaluate the current 64X forward earnings valuation against the company's strong growth projections and the potential for upward EPS revisions.
• Consider the long-term implications of the expanding installed base of over 10,000 systems, which underpins future recurring revenue streams and market dominance in robotic surgery.